A Canadian research team found low doses of the blood thinner rivaroxaban, marketed as Xarelto from Johnson & Johnson unit Janssen Pharmaceuticals, reduced the risk of blood clot recurrence by about 70% compared with aspirin, without increasing the risk of bleeding.

Sections:  business   
Topics:  health   
RELATED ARTICLES
    BING NEWS:
    • Aspirin shows no benefit in preventing breast cancer recurrence, study finds
      To summarize, in the recent trial, aspirin at 300 mg/day showed no benefit in improving IDFS in patients with high-risk early breast cancer. Despite shorter follow-up, the trial crossed the ...
      05/2/2024 - 2:12 am | View Link
    • Georgetown study raises concerns over aspirin's role in breast cancer treatment
      A new study examining the role of aspirin in breast cancer treatment reveals critical issues related to health equity and aging that have broad implications for cancer and other disease intervention ...
      04/30/2024 - 7:52 am | View Link
    • Experimental Blood Thinner Can Be Reversed With Fast-Acting Antidote
      Researchers developed an experimental anticoagulant, or blood thinner, that blocks the activity of a protein involved in the formation of blood clots. The drug’s action can be rapidly reversed with an ...
      04/30/2024 - 4:34 am | View Link
    • More

     

    Welcome to Wopular!

    Welcome to Wopular

    Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

    Senh Duong (Founder)
    Wopular, MWB, RottenTomatoes

    Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

    MoviesWithButter : Our Sister Site

    More News